Abstract
An open label study was conducted to asses the efficacy and safety of rosiglitazone when administered concurrently withsulphonylurea compounds. Sixty-three type 2 diabetic patients were enrolled in the study in three different centres acrossNigeria, Zaria in the north, Lagos in the southwest and Port Harcourt in the southeast. Nigeria is a large country with multiethnicgroups. Subjects were randomly divided into two treatment groups; one on only sulphonylurea and the other onrosiglitazone (4 mg daily) for 26 weeks in addition to the current dose of sulphonylurea. Fifty-two subjects (82.5%)completed the study. The addition of rosiglitazone to sulphonylurea therapy resulted in more steady control of fasting plasmaglucose (FPG) over time, higher mean change in FPG from baseline and higher proportion of subjects recording HBA1Cvalue of <7.5. There were no significant adverse events attributable to rosiglitazone therapy during the 26 weeks of therapy. Itis concluded that the addition of rosiglitazone to sulphonylurea treatment is safe and has a synergistic effect in controllingglycaemia in type 2 diabetic patients. (Int J Diabetes Metab 15:62-67, 2007)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
